Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience.

@article{Kuo2017DocetaxelBA,
  title={Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience.},
  author={Christopher Kuo and Paul M. Kent and Antonio D Logan and Karen B Tamulonis and Kristen L Dalton and Marta Batus and Karen S Fern{\'a}ndez and Rebecca E Mcfall},
  journal={Pediatric blood & cancer},
  year={2017},
  volume={64 4}
}
BACKGROUND Adolescent and young adult (AYA) patients with very high risk sarcomas have poor outcomes and are in need of novel therapies. PROCEDURE From January 2005 to February 2016, we retrospectively identified all AYA patients with relapsed or metastatic high-grade sarcomas, who were treated with at least one cycle of docetaxel (T), bevacizumab (A), and gemcitabine (G) (TAG ; T = 100 mg/m2 Day 8, A = 15 mg/kg Day 1, G = 1,000 mg/m2 Days 1 and 8). RESULTS Fourteen patients, median age of… CONTINUE READING